Lalwani Nikhil 4
4 · ANI PHARMACEUTICALS INC · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
ANI Pharmaceuticals CEO Nikhil Lalwani Withholds Shares for Taxes
What Happened
Nikhil Lalwani, President & CEO and a director of ANI Pharmaceuticals (ANIP), had 17,060 shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock. The withholding is reported as a disposition at $74.04 per share, totaling $1,263,122. This was a tax-withholding event related to an award vesting—not an open-market sale or purchase.
Key Details
- Transaction date: March 7, 2026; Form filed March 10, 2026 (filing appears timely).
- Withheld/disposed: 17,060 shares at $74.04 per share; aggregate value reported $1,263,122.
- Underlying award: 33,352 restricted shares vested (previously reported); F1 footnote says shares were withheld for tax purposes and the transaction is exempt under Rule 16b-3.
- Shares owned after transaction: not specified in the provided summary.
- Transaction code: F (tax withholding/ payment of exercise price or tax liability).
Context
Tax-withholding dispositions are routine when restricted stock vests and do not necessarily signal the insider’s view of the company’s prospects. The Form 4 reports the withholding as a disposition for tax purposes; because the withholding is exempt under Rule 16b-3, it generally isn’t subject to short-swing profit recovery. Purchases or open-market sales typically provide clearer signals of insider sentiment than tax-withholding events.
Insider Transaction Report
- Tax Payment
Common Stock
[F1]2026-03-07$74.04/sh−17,060$1,263,122→ 404,889 total
Footnotes (1)
- [F1]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported.